A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile

Recently, a series of highly effective peptide- or protein-based HIV fusion inhibitors have been identified. However, due to their short half-life, their clinical application is limited. Therefore, the development of long-acting HIV fusion inhibitors is urgently needed. Here, we designed and constru...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wei, Cong, Zhe, Duan, Qianyu, Wang, Qian, Su, Shan, Wang, Rui, Lu, Lu, Xue, Jing, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025429/
https://www.ncbi.nlm.nih.gov/pubmed/35455421
http://dx.doi.org/10.3390/ph15040424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025429/
https://www.ncbi.nlm.nih.gov/pubmed/35455421
http://dx.doi.org/10.3390/ph15040424

Ejemplares similares